Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Hadasit Medical Research Services & Development Limited is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner within a distinct art unit. SCHLIENTZ, LEAH H is the busiest examiner for the portfolio, with the pending office action. This pending action constitutes the full extent of the company's current pending prosecution across the art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 3 (50%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTANARI, DAVID A | 1 | 64.7% | +49.0% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| MEYERING, SHABANA SHABBEER | 1 | 70.6% | +42.3% |
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| FONTAINHAS, AURORA M | 1 | 37.9% | +49.2% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292918 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | JARRELL, NOBLE E | — |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | MEYERING, SHABANA SHABBEER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18157438 | METHODS AND SYNERGIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | WELLS, LAUREN QUINLAN | 6d |
| 18866750 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | MONTANARI, DAVID A | — |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | MEYERING, SHABANA SHABBEER | — |
| 18058425 | METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS | FONTAINHAS, AURORA M | — |
| 17528699 | METHOD AND KIT FOR DETERMINING THE TISSUE OR CELL ORIGIN OF DNA | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1699 | 1 |
| 4100 | 1 |
| 1622 | 1 |
| 1675 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866750 | GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY | MONTANARI, DAVID A | 1632 | §103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18292918 | COMPOUNDS FOR NEUTROPHIL ROS INHIBITION | JARRELL, NOBLE E | 1699 | §102§112 | Non-Final OA | — | Pending | Jan 28, 2024 |
| 18390880 | VARIANT-SPECIFIC EXOGENOUS DNA TEMPLATE-FREE CORRECTION OF PATHOGENIC VARIANTS | MEYERING, SHABANA SHABBEER | 4100 | §102§103§112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18157438 | METHODS AND SYNERGIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | WELLS, LAUREN QUINLAN | 1622 | §103§112DP | Non-Final OA | 6d | Pending | Jan 20, 2023 |
| 18058425 | METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS | FONTAINHAS, AURORA M | 1675 | §112DP | Non-Final OA | — | Pending | Nov 23, 2022 |
| 17528699 | METHOD AND KIT FOR DETERMINING THE TISSUE OR CELL ORIGIN OF DNA | GOLDBERG, JEANINE ANNE | 1682 | §112DP | Non-Final OA | — | Pending | Nov 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial